Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.
Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roé-Vellvé N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M. Bullich S, et al. Among authors: kanekiyo m. Alzheimers Res Ther. 2022 Jul 27;14(1):105. doi: 10.1186/s13195-022-01048-x. Alzheimers Res Ther. 2022. PMID: 35897078 Free PMC article. Clinical Trial.
Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. Among authors: kanekiyo m. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. McDade E, et al. Among authors: kanekiyo m. Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Alzheimers Res Ther. 2022. PMID: 36544184 Free PMC article. Clinical Trial.
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
Grill JD, Flournoy C, Dhadda S, Ernstrom K, Sperling R, Molina-Henry D, Tranotti K, Harris R, Kanekiyo M, Gee M, Irizarry M, Kramer L, Aisen P, Raman R. Grill JD, et al. Among authors: kanekiyo m. Ann Neurol. 2024 Feb;95(2):288-298. doi: 10.1002/ana.26819. Epub 2023 Oct 25. Ann Neurol. 2024. PMID: 37830926 Clinical Trial.
Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L. Honig LS, et al. Among authors: kanekiyo m. Alzheimers Res Ther. 2024 May 10;16(1):105. doi: 10.1186/s13195-024-01441-8. Alzheimers Res Ther. 2024. PMID: 38730496 Free PMC article. Clinical Trial.
Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Yagi T, Kanekiyo M, Ito J, Ihara R, Suzuki K, Iwata A, Iwatsubo T, Aoshima K; Alzheimer's Disease Neuroimaging Initiative; Japanese Alzheimer's Disease Neuroimaging Initiative. Yagi T, et al. Among authors: kanekiyo m. Alzheimers Dement (N Y). 2019 Aug 7;5:364-373. doi: 10.1016/j.trci.2019.06.004. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31440579 Free PMC article.
110 results